HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-1556v1 31/1/140    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Quattrini, C. Articles by Malik, R. A. Search for Related Content PubMed PubMed Citation Articles by Quattrini, C. Articles by Malik, R. A. Social Bookmarking                What's this?

Reduced Vascular Endothelial Growth Factor Expression and Intra-Epidermal Nerve Fiber Loss in Human Diabetic Neuropathy

¹ Division of Cardiovascular Medicine, University of Manchester and Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K
² Division of Regenerative Medicine, University of Manchester, Manchester, U.K

Address correspondence and reprint requests to Dr. R.A. Malik, Division of Cardiovascular Medicine, Core Technology Facility, University of Manchester, Manchester, M13 9NT, U.K. E-mail: rayaz.a.malik{at}man.ac.uk

OBJECTIVE—To assess the relevance of vascular endothelial growth factor (VEGF) in the maintenance of peripheral nerve integrity in diabetic neuropathy we have assessed the expression of VEGF and intra-epidermal nerve fiber density (IENFD) in skin biopsy samples from diabetic patients.

RESEARCH DESIGN AND METHODS—Fifty-three diabetic patients and 12 nondiabetic control subjects underwent neurological evaluation, electrophysiology, quantitative sensory, and autonomic function testing. Dermal blood flow responses were evaluated with laser Doppler flowmetry. Skin biopsies were performed on the dorsum of the foot, and IENFD was quantified and compared with the expression of vascular endothelial growth factor A (VEGF-A), its receptor vascular endothelial growth factor receptor 2 (VEGFR-2), hypoxia-inducible factor 1 (HIF-1), and microvessel density.

RESULTS—IENFD decreased progressively with increasing severity of diabetic neuropathy (P < 0.001). The dermal blood flow response to acetylcholine was reduced in diabetic patients with mild and moderate neuropathy (P < 0.01), and the intensity of staining for epidermal VEGF-A was significantly reduced in diabetic patients compared with control subjects (P < 0.01). Epidermal HIF-1 and VEGFR-2 expression did not differ between groups.

CONCLUSIONS—Progressive endothelial dysfunction, a reduction in VEGF expression, and loss of intra-epidermal nerve fibers occurs in the foot skin of diabetic patients with increasing neuropathic severity.

Abbreviations: HIF-1, hypoxia-inducible factor 1 • IENF, intra-epidermal nerve fiber • IENFD, intra-epidermal nerve fiber density • NDS, neuropathy disability score • VAS, visual analog score • VEGF, vascular endothelial growth factor • VEGF-A, vascular endothelial growth factor A • VEGFR-2, vascular endothelial growth factor receptor 2

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?